文献速递呼吸道感染呼吸危重症与机械通气

糖皮质激素对COVID-19结局影响的系统综述与荟萃分析

Impact of Corticosteroids in Coronavirus Disease 2019 Outcomes: Systematic Review and Meta-analysis.
PubMed 文献 · Chest · 2020-10-28

该研究系统检索截至2020年7月22日的文献,纳入73项研究共21350例COVID-19患者,比较使用与未使用糖皮质激素者的结局。

要点

  • 重症COVID-19患者使用糖皮质激素与死亡率获益相关。
  • 高剂量或低剂量激素方案未见显著有益或有害效应。
  • 低剂量激素对SARS-CoV-2病毒排毒时长无显著影响。

核心结论

  • 重症COVID-19患者接受糖皮质激素治疗与死亡率获益相关。

研究设计与样本

  • 系统综述与荟萃分析,检索PubMed、MEDLINE和EMBASE截至2020年7月22日的文献。
  • 纳入73项报告COVID-19患者使用糖皮质激素并有对照组的结局研究,共21350例患者。

主要发现

  • 糖皮质激素使用在机械通气患者中报告率为35.3%,ICU患者为51.3%,重症COVID-19患者为40%。
  • 高剂量或低剂量糖皮质激素方案未见有益或有害效应。
  • 低剂量糖皮质激素对SARS-CoV-2病毒排毒时长无显著影响。

临床怎么用

  • 对重症COVID-19患者可考虑使用糖皮质激素以降低死亡风险。
  • 高剂量或低剂量方案的选择尚缺乏明确获益证据,需个体化评估。

局限性

  • 高剂量和低剂量糖皮质激素方案的相关文献异质性高。
  • 需要进一步高质量临床试验明确最佳时机和剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Since its appearance in late 2019, infections caused by severe acute respiratory syndrome coronavirus 2 have created unprecedented challenges for health systems worldwide. Multiple therapeutic options have been explored, including corticosteroids. Preliminary results of corticosteroids in coronavirus disease 2019 (COVID-19) are encouraging; however, the role of corticosteroids remains controversial. RESEARCH QUESTION: What is the impact of corticosteroids in mortality, ICU admission, mechanical ventilation, and viral shedding in COVID-19 patients? STUDY DESIGN AND METHODS: We conducted a systematic review of literature on corticosteroids and COVID-19 in major databases (PubMed, MEDLINE, and EMBASE) of published literature through July 22, 2020, that report outcomes of interest in COVID-19 patients receiving corticosteroids with a comparative group. RESULTS: A total of 73 studies with 21,350 COVID-19 patients were identified. Corticosteroid use was reported widely in mechanically ventilated patients (35.3%), ICU patients (51.3%), and severe COVID-19 patients (40%). Corticosteroids showed mortality benefit in severelly ill COVID-19 patients (OR, 0.65; 95% CI, 0.51-0.83; P = .0006); however, no beneficial or harmful effects were noted among high-dose or low-dose corticosteroid regimens. Emerging evidence shows that low-dose corticosteroids do not have a significant impact in the duration of SARS-CoV-2 viral shedding. The analysis was limited by highly heterogeneous literature for high-dose and low-dose corticosteroids regimens. INTERPRETATION: Our results showed evidence of mortality benefit in severely ill COVID-19 patients treated with corticosteroids. Corticosteroids are used widely in COVID-19 patients worldwide, and a rapidly developing global pandemic warrants further high-quality clinical trials to define the most beneficial timing and dosing for corticosteroids.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Cano EJ, Fonseca Fuentes X, Corsini Campioli C, et al. Impact of Corticosteroids in Coronavirus Disease 2019 Outcomes: Systematic Review and Meta-analysis. Chest. 2020. PMID: 33129791. doi:10.1016/j.chest.2020.10.054

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。